Cellosaurus logo
expasy logo

Cellosaurus OVCAR-3 (CVCL_0465)

[Text version]
Cell line name OVCAR-3
Synonyms Ovcar-3; OVCAR 3; OVCAR.3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR3; Ovcar3
Accession CVCL_0465
Resource Identification Initiative To cite this cell line use: OVCAR-3 (RRID:CVCL_0465)
Comments Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: JFCR39 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Part of: OCCP ovarian cancer cell line panel.
Population: Caucasian.
Doubling time: 48 hours (PubMed=6604576); 35 hours (PubMed=2653399); 64 hours (PubMed=25984343); 34.7 hours (NCI-DTP=OVCAR-3); ~69 hours (PBCF); 53.77 hours (GrayJW panel).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Exosome proteome analysis.
Omics: Fluorescence phenotype profiling.
Omics: Genome sequenced.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: N-glycan profiling.
Omics: O-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: OVCA3; Note=Occasionally.
Misspelling: OVOCAR3; Note=Occasionally.
Misspelling: OVCAK3; GEO=GSM459741.
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
HLA typing Source: PubMed=15748285
Class I
HLA-AA*02:01:01,29:02
HLA-BB*07:02:01,58:01
HLA-CC*07:02:01,07
Class II
HLA-DPDPB1*02:01:02,04:01
HLA-DQDQB1*04:02
HLA-DRDRB1*08:01:01,08:04:01

Source: PubMed=26589293
Class I
HLA-AA*02:01,29:02
HLA-BB*07:02,58:01
HLA-CC*07:02,07:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North3.99
East Asian, South0
South Asian0
European, North60.92
European, South35.08
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_1882 (ONCO-DG-1)CVCL_Y033 (OV(hyg)CAR3)CVCL_S033 (OVCAR-3 SimpleCell O-GalNAc)
CVCL_C8Y2 (OVCAR-3-Luc)CVCL_4Y18 (OVCAR-3/CMV-Luc)CVCL_DA03 (OVCAR-3/T40)
CVCL_DA02 (OVCAR-3/TxT5)CVCL_DH37 (OVCAR3-533533-R1)CVCL_DH38 (OVCAR3-533533-R3)
CVCL_DH39 (OVCAR3-533533-R5)CVCL_DH40 (OVCAR3-533533-R6)CVCL_DH41 (OVCAR3-533533-R7)
Sex of cell Female
Age at sampling 60Y
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; CLS; COG; Cosmic-CLP; Genomics_Center_BCF_Technion; KCLB; Millipore; PubMed=19372543; PubMed=25230021; PubMed=25877200; PubMed=30485824; RCB; TKG

Markers:
AmelogeninX
CSF1PO11,12
D1S165612,17.3
D2S44111,14
D2S133817,21
D3S135817,18
D5S81811,12
D7S82010
D8S117910,15
D10S124813,15
D12S39122
D13S31712
D16S53912
D18S5113
D19S43316.2
D21S1129,31.2
D22S104516
FGA21
Penta D12,13
Penta E7,13
TH019 (Genomics_Center_BCF_Technion; Millipore)
9,9.3 (ATCC; CCRID; CLS; COG; Cosmic-CLP; KCLB; PubMed=19372543; PubMed=25230021; PubMed=25877200; RCB; TKG)
9.3 (PubMed=30485824)
TPOX8
vWA17

Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://www.atcc.org/en/support/technical-support/faqs/morphology-of-atcc-htb-161
https://www.synapse.org/#!Synapse:syn31544485
https://strap.nci.nih.gov/celline_detail.php?sample_id=22
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=OVCAR-3
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/o/cell-lines-detail-239.html
https://tcpaportal.org/mclp/
Publications

PubMed=6604576
Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., Ozols R.F.
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.
Cancer Res. 43:5379-5389(1983)

PubMed=6372095; DOI=10.1126/science.6372095
Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W. Jr., Ozols R.F.
Reversal of adriamycin resistance by verapamil in human ovarian cancer.
Science 224:994-996(1984)

PubMed=6385258
Hamilton T.C., Young R.C., Ozols R.F.
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.
Semin. Oncol. 11:285-298(1984)

PubMed=3930572; DOI=10.1172/JCI112082
Pirker R., FitzGerald D.J.P., Hamilton T.C., Ozols R.F., Laird W.J., Frankel A.E., Willingham M.C., Pastan I.
Characterization of immunotoxins active against ovarian cancer cell lines.
J. Clin. Invest. 76:1261-1267(1985)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2653399; DOI=10.1038/bjc.1989.108
Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R.
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Br. J. Cancer 59:527-534(1989)

PubMed=2307530; DOI=10.1002/ijc.2910450306
Schilder R.J., Hall L., Monks A., Handel L.M., Fornace A.J. Jr., Ozols R.F., Fojo A.T., Hamilton T.C.
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.
Int. J. Cancer 45:416-422(1990)

PubMed=1892748; DOI=10.1038/bjc.1991.279
Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Br. J. Cancer 64:215-220(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=1348364; DOI=10.1073/pnas.89.7.3070
Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C., Anderson M.E.
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992)

PubMed=8557231; DOI=10.1006/gyno.1996.0014
Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.
p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Gynecol. Oncol. 60:72-80(1996)

PubMed=9041185
Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Cancer Res. 57:850-856(1997)

PubMed=9698466; DOI=10.1006/gyno.1998.5039
Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., Berchuck A., Futreal P.A.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecol. Oncol. 70:13-16(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11793438; DOI=10.1002/gcc.1221
Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.
Multicolor spectral karyotyping of serous ovarian adenocarcinoma.
Genes Chromosomes Cancer 33:123-132(2002)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x
Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=16382445; DOI=10.1002/gcc.20300
Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K., Chen X., Sikic B.I.
Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.
Genes Chromosomes Cancer 45:365-374(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=18560578; DOI=10.1371/journal.pone.0002425
Faca V.M., Ventura A.P., Fitzgibbon M.P., Pereira-Faca S.R., Pitteri S.J., Green A.E., Ireton R.C., Zhang Q., Wang H., O'Briant K.C., Drescher C.W., Schummer M., McIntosh M.W., Knudsen B.S., Hanash S.M.
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.
PLoS ONE 3:E2425-E2425(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS
DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E., Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.
S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
Am. J. Clin. Pathol. 132:846-856(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20204287; DOI=10.3892/or_00000728
Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Oncol. Rep. 23:1021-1026(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z
Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Invest. New Drugs 30:2035-2045(2012)

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170
Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer Discov. 2:56-67(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23172893; DOI=10.1074/mcp.M112.019521
Marzinke M.A., Choi C.H., Chen L., Shih I.-M., Chan D.W., Zhang H.
Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.
Mol. Cell. Proteomics 12:356-368(2013)

PubMed=23351415; DOI=10.1016/j.jcma.2012.08.023
Chao K.-C., Wang P.-H., Chang C.-C., Yen M.-S., Chi C.-W.
The role of estrogen in the survival of ovarian tumors -- a study of the human ovarian adenocarcinoma cell lines OC-117-VGH and OVCAR3.
J. Chin. Med. Assoc. 76:63-70(2013)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126.1-2126.10(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070
Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S., Kislinger T.
In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem. Biophys. Res. Commun. 445:694-701(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26169745; DOI=10.1186/s12967-015-0576-z
Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D., Suhre K., Rafii A.
Metabolic signatures differentiate ovarian from colon cancer cell lines.
J. Transl. Med. 13:223.1-223.12(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028
Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Gynecol. Oncol. 142:332-340(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645.1-12645.14(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28100988; DOI=10.1186/s12014-017-9137-1
Yang S., Hoti N., Yang W.-M., Liu Y., Chen L.-J., Li S.-W., Zhang H.
Simultaneous analyses of N-linked and O-linked glycans of ovarian cancer cells using solid-phase chemoenzymatic method.
Clin. Proteomics 14:3.1-3.11(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32612269; DOI=10.1038/s41598-020-67533-1
De Haven Brandon A., Box G., Hallsworth A., Court W., Matthews N., Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
Sci. Rep. 10:10799-10799(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) Abcam; ab275471
ATCC; HTB-161
BCRC; 60551
BCRJ; 0317
CCTCC; GDC0119
CLS; 300307
ICLC; HTL97004 - Discontinued
IZSLER; BS TCL 131
KCB; KCB 2006106YJ
KCLB; 30161
Millipore; SCC257
NCBI_Iran; C430
NCI-DTP; OVCAR-3
RCB; RCB2135
TKG; TKG 0602
Ubigene; YC-D019
Cell line databases/resources CLO; CLO_0008171
CLO; CLO_0008279
CLO; CLO_0051451
MCCL; MCC:0000363
CLDB; cl3712
CLDB; cl3780
CLDB; cl5237
cancercelllines; CVCL_0465
CCRID; 1101HUM-PUMC000362
CCRID; 3101HUMTCHu228
CCRID; 4201HUM-CCTCC00119
Cell_Model_Passport; SIDM00105
Cosmic-CLP; 905933
DepMap; ACH-000001
IGRhCellID; OVCAR3
LINCS_LDP; LCL-1522
Lonza; 31
SKY/M-FISH/CGH; 2742
TOKU-E; 2754
Anatomy/cell type resources BTO; BTO:0000812
Biological sample resources BioSample; SAMN01821585
BioSample; SAMN03471390
BioSample; SAMN05292457
BioSample; SAMN10987888
ENCODE; ENCBS419ENC
CRISP screens repositories BioGRID_ORCS_Cell_line; 981
Chemistry resources ChEMBL-Cells; CHEMBL3307564
ChEMBL-Targets; CHEMBL614213
GDSC; 905933
PharmacoDB; OVCAR3_1217_2019
PubChem_Cell_line; CVCL_0465
Encyclopedic resources Wikidata; Q54937005
Experimental variables resources EFO; EFO_0003061
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM2122
GEO; GSM50219
GEO; GSM50282
GEO; GSM95463
GEO; GSM185135
GEO; GSM185136
GEO; GSM274703
GEO; GSM313683
GEO; GSM459733
GEO; GSM459741
GEO; GSM645843
GEO; GSM659393
GEO; GSM711708
GEO; GSM743474
GEO; GSM743498
GEO; GSM750817
GEO; GSM784564
GEO; GSM799362
GEO; GSM799363
GEO; GSM799425
GEO; GSM799426
GEO; GSM847106
GEO; GSM844668
GEO; GSM851934
GEO; GSM887456
GEO; GSM888536
GEO; GSM1001493
GEO; GSM1153434
GEO; GSM1153435
GEO; GSM1178508
GEO; GSM1178509
GEO; GSM1181276
GEO; GSM1181278
GEO; GSM1186813
GEO; GSM1186814
GEO; GSM1186815
GEO; GSM1186816
GEO; GSM1186827
GEO; GSM1291149
GEO; GSM1374771
GEO; GSM1374772
GEO; GSM1374773
GEO; GSM1670317
GEO; GSM2124645
GEO; GSM2474989
Metabolomic databases MetaboLights; MTBLS150
MetaboLights; MTBLS152
Polymorphism and mutation databases Cosmic; 687926
Cosmic; 688104
Cosmic; 755845
Cosmic; 809113
Cosmic; 844347
Cosmic; 845142
Cosmic; 875859
Cosmic; 897433
Cosmic; 905933
Cosmic; 906577
Cosmic; 920357
Cosmic; 924144
Cosmic; 927564
Cosmic; 949227
Cosmic; 974296
Cosmic; 991321
Cosmic; 1044239
Cosmic; 1092623
Cosmic; 1093553
Cosmic; 1102816
Cosmic; 1139222
Cosmic; 1175883
Cosmic; 1218877
Cosmic; 1305312
Cosmic; 1312192
Cosmic; 1312354
Cosmic; 1436033
Cosmic; 1482525
Cosmic; 1524357
Cosmic; 1709250
Cosmic; 1998465
Cosmic; 2186584
IARC_TP53; 1417
LiGeA; CCLE_502
Progenetix; CVCL_0465
Proteomic databases PRIDE; PXD003105
PRIDE; PXD003668
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number45